Skip to content

JAK-STAT pathway

Physiology/Biochemistry/PharmacologyHematologicImmuneEndocrine

Summary

The JAK-STAT pathway is a signal transduction cascade used by cytokine receptors (lacking intrinsic kinase activity) to transmit signals from the cell surface to the nucleus, regulating gene transcription. Janus kinases (JAKs) phosphorylate STAT proteins, which dimerize and translocate to the nucleus to modulate gene expression. It's crucial for hematopoiesis, immune cell development, and growth signaling, and is a target for several immunosuppressive/anti-inflammatory drugs.

Detail

Mechanism: Cytokines (e.g., IL-2, IL-6, IFN-γ, EPO, GH, TPO) bind to their receptors, causing receptor dimerization. This juxtaposes receptor-associated JAK kinases (JAK1, JAK2, JAK3, TYK2), which trans-phosphorylate each other and the receptor's cytoplasmic tail. Phosphorylated tyrosines serve as docking sites for STAT proteins (STAT1-6), which are then phosphorylated by JAKs. Phosphorylated STATs dimerize (via SH2 domains) and translocate to the nucleus, where they act as transcription factors binding specific DNA response elements to regulate gene expression involved in cell proliferation, differentiation, apoptosis, and immune function.

Clinical significance: - JAK2 V617F mutation: constitutively active JAK2 causing myeloproliferative disorders—polycythemia vera (near 100%), essential thrombocythemia, and primary myelofibrosis (~50-60%). This mutation makes hematopoietic cells hypersensitive to growth factors like EPO, TPO. - JAK3 mutations: associated with X-linked SCID (severe combined immunodeficiency) since JAK3 pairs with the common gamma chain used by IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 receptors—critical for lymphocyte development. - STAT3 mutations: associated with Hyper-IgE syndrome (Job syndrome), affecting Th17 differentiation.

Pharmacology (JAK inhibitors - "-tinib" drugs): - Ruxolitinib (JAK1/2 inhibitor): used for myelofibrosis, polycythemia vera. - Tofacitinib (JAK1/3 inhibitor): used for rheumatoid arthritis, ulcerative colitis. - Baricitinib (JAK1/2 inhibitor): rheumatoid arthritis, alopecia areata, COVID-19 (in combination with remdesivir). - Side effects of JAK inhibitors: increased infection risk (including reactivation of TB, herpes zoster), cytopenias, increased risk of thrombosis and malignancy (boxed warning), and hyperlipidemia.

This pathway is distinct from RTK-Ras-MAPK pathway (used by growth factor receptors like EGFR) and is specifically utilized by type I and type II cytokine receptors.

Sources

  • First Aid for the USMLE Step 1
  • Robbins and Cotran Pathologic Basis of Disease
  • Katzung's Basic and Clinical Pharmacology
  • Lippincott Illustrated Reviews: Immunology

Reviewed by AnkiBoss editorial — medical student review. Information here is for study reference only and is not medical advice. Spotted an error? Let us know.